AbCellera Biologics Inc. Non Peo Neo Avg Total Comp Amt
AbCellera Biologics Inc. (ABCL) reported Non Peo Neo Avg Total Comp Amt of $2.68 million for the 12-month period ending 2025-12-31, per its DEF 14A filed 2026-04-29.
Financial Statements › Notes
ecd:NonPeoNeoAvgTotalCompAmt · last filed 2026-04-29
| Period end | Non Peo Neo Avg Total Comp Amt 12 month |
|---|---|
| 2025-12-31 | $2.68M DEF 14A · filed 2026-04-29 |
| 2024-12-31 | $3.25M DEF 14A · filed 2026-04-29 |
| 2023-12-31 | $664.28K DEF 14A · filed 2026-04-29 |
| 2022-12-31 | $4.71M DEF 14A · filed 2026-04-29 |
| 2021-12-31 | $4.07M DEF 14A · filed 2026-04-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |